BioMarin Pharmaceutical (BMRN) to Release Earnings on Thursday

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect BioMarin Pharmaceutical to post earnings of $0.54 per share and revenue of $711.05 million for the quarter. BioMarin Pharmaceutical has set its FY 2025 guidance at 4.200-4.400 EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a return on equity of 10.10% and a net margin of 14.96%. On average, analysts expect BioMarin Pharmaceutical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

BioMarin Pharmaceutical Trading Down 0.4 %

BMRN traded down $0.25 during trading on Friday, reaching $68.48. The company had a trading volume of 901,147 shares, compared to its average volume of 1,573,545. The firm's 50-day simple moving average is $64.84 and its 200 day simple moving average is $71.05. The company has a market cap of $13.05 billion, a price-to-earnings ratio of 31.11, a PEG ratio of 0.58 and a beta of 0.28. BioMarin Pharmaceutical has a 12-month low of $60.63 and a 12-month high of $94.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27.

Wall Street Analysts Forecast Growth

BMRN has been the topic of a number of analyst reports. Citigroup lifted their price target on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a "neutral" rating in a research note on Thursday. William Blair cut BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, October 30th. Scotiabank lifted their price target on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday. Canaccord Genuity Group dropped their price target on BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating on the stock in a research note on Wednesday, October 30th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $70.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $93.81.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.